UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2024
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Emma Walmsley | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.1128 | 1,840.922 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Diana Conrad | |||
| b) | Position/status | Chief People Officer | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.1128 | 724.675 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | James Ford | |||
| b) | Position/status | Senior Vice President and Group General Counsel | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.1128 | 1,268.806 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Sally Jackson | |||
| b) | Position/status | SVP, Global Communications and CEO Office | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.1128 | 638.941 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dylan Jackson | |||
| b) | Position/status | PCA of Sally Jackson (SVP, Global Communications and CEO Office) | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.1128 | 279.316 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Luke Miels | |||
| b) | Position/status | Chief Commercial Officer | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.1128 | 7,785.656 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | David Redfern | |||
| b) | Position/status | President Corporate Development | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.1128 | 5,128.081 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Regis Simard | |||
| b) | Position/status | President, Global Supply Chain | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.1128 | 1,733.135 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Phil Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.1128 | 1,663.115 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Kate Thomson | |||
| b) | Position/status | PCA of Phil Thomson (President, Global Affairs) | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.1128 | 104.433 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Deborah Waterhouse | |||
| b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.1128 | 1,077.954 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Tony Wood | |||
| b) | Position/status | Chief Scientific Officer | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.1128 | 596.088 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Hal Barron | |||
| b) | Position/status | Non-Executive Director | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$39.7942 | 2,906.213 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $39.7942 | 313.616 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Shobie Ramakrishnan | |||
| b) | Position/status | Chief Digital and Technology Officer | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$39.7942 | 154.801 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-04-16 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) | |||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
| (Registrant) | |
| Date: April 19, 2024 | |
By:/s/ VICTORIA WHYTE -------------------------- | |
| Victoria Whyte | |
| Authorised Signatory for and on | |
| behalf of GSK plc |